EirGenix, Inc.
6589.TW
Taiwan Stock Exchange48.70
TWD
- -
- -
EirGenix, Inc.
6589.TW
(Taiwan Stock Exchange)
Recent
price
48.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- EirGenix, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics and related services. The company designs and delivers high-quality genetic, cellular, and molecular solutions across research, diagnostic, and therapeutic applications, leveraging its expertise in genetic engineering, protein expression, and assay development to support pharmaceutical, biotech, and academic customers. Main Products and Services: - Genomic and molecular biology services: gene synthesis and editing services, vector construction, CRISPR design and validation, DNA sequencing and genotyping, and related gene-therapy enabling platforms - Protein and biologics development: expression and purification of recombinant proteins, antibody discovery and engineering, protein engineering and optimization, and assay development for biomarker validation - Cellular biology and gene therapy support: cell line development, transduction and transfection services, viral vector production, scale-up for preclinical and early clinical studies, and functional screening assays - Diagnostic and analytical services: assay development and qualification, analytical method development and validation, quality control testing, and biomarker discovery support - Platform and enabling technologies: proprietary expression systems, high-throughput screening capabilities, cell culture optimization, and bioinformatics support for data analysis and interpretation - Regulatory and consulting support: product characterization documentation, GMP-compliant process development guidance, and regulatory strategy input for preclinical and clinical programs Geographic Operations: - Headquarters and core operations are located in Taiwan - Serves global customers with R&D, manufacturing, and testing capabilities across Asia-Pacific, with downstream collaboration and client support across multiple regions Founding Year and Ownership: - Founded in 2010 (founding year and ongoing headquarters-based operations noted) Industry and Segments: - Industry: biotechnology and life sciences - Segments include contract research and development services (CRDS), contract manufacturing services (CMS) for biologics, and enabling technology platforms for genetic and cellular therapeutics Target Markets and Customers: - Pharmaceutical and biotechnology companies conducting translational research, preclinical studies, and early-stage clinical development - Academic and government research institutions requiring specialized molecular biology, protein production, and assay development services Subsidiaries and Corporate Relationships: - Operates as an independent company with a focus on contract research and manufacturing services; relationship to larger corporate groups or parent organizations is not specified in public disclosures Recent Major Changes and Developments (latest 1–2 years): - Strategic partnerships or alliances with pharmaceutical or biotech entities to advance gene therapy and protein development programs - Acquisitions or minority investments expanding capabilities in gene editing platforms, vector production, or analytical services - New product launches or service expansions introducing enhanced gene therapy vector production, scalable protein expression platforms, or expanded diagnostic assay development offerings - Business expansions into additional geographic regions or new regional service centers to support global client base - Reorganization or branding updates to reflect expanded capabilities or new strategic focus areas - Significant operational changes such as capex investments in manufacturing facilities, implementation of GMP-compliant processes, or scale-up of bioprocessing capabilities Additional Context: - Core focus areas include genetic engineering, protein expression, cell-based assays, and diagnostic development - Primary customers are research-driven biotechs and larger pharma clients seeking specialized CRO/CMO services - Geographic reach centers on Taiwan with regional outreach to Asia-Pacific and global client support through collaborative projects and contract services - No publicly disclosed parent company relationships; operates as a standalone entity with potential strategic collaborations Note: Information above reflects the most current public-facing profile and typical structuring of a biotechnology services firm; for precise product names, service categorizations, and the latest signed partnerships, funding rounds, or corporate actions, refer to the company’s official communications and recent regulatory filings.